American Regent vs. RK Pharma: Voluntary Dismissal in Trace Elements Patent Dispute in Delaware
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | American Regent, Inc. v. RK Pharma Inc. |
| Case Number | 1:24-cv-00268 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Feb 2024 – Apr 2024 41 days |
| Outcome | Voluntary Dismissal (Plaintiff) |
| Patents at Issue | |
| Accused Products | Trace Elements Injection 4*, USP in 1 mL single-dose vials and 5 mL Pharmacy Bulk Package vials |
Case Overview
The Parties
⚖️ Plaintiff
New York-based pharmaceutical company specializing in injectable drug products, including iron therapies and specialty injectables used in hospital and clinical environments.
🛡️ Defendant
Pharmaceutical manufacturer, joined by ARCHIS PHARMA LLC, Apicore US, LLC, and Vgyaan Pharmaceuticals, LLC, suggesting a supply-chain enforcement strategy.
The Patent at Issue
The patent at the center of this dispute, U.S. Patent No. US11786548B2 (application number US17/365695), covers innovations in trace elements injection formulations. Trace elements injections are critical components of parenteral nutrition therapy administered to patients who cannot receive nutrition orally. Protecting formulation specifics and delivery mechanisms in this product category is commercially significant.
- • US11786548B2 — Innovations in trace elements injection formulations
Developing a similar pharmaceutical product?
Check if your formulation might infringe this or related patents before market entry.
The Verdict & Legal Analysis
Outcome
American Regent filed a voluntary dismissal without prejudice on April 10, 2024, terminating all claims against all defendants before any substantive rulings were issued. No damages were awarded, no injunctive relief was granted, and no merit-based findings were recorded. The “without prejudice” designation is legally significant: American Regent retains the right to re-file the same claims in the future, subject to applicable statutes of limitations and procedural constraints.
Key Legal Issues
The complaint was grounded in a straightforward patent infringement action. However, the rapid voluntary dismissal, occurring before any defendant formally appeared on record, points to a strategic exit. The dismissal was executed pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), which permits a plaintiff to voluntarily dismiss an action without a court order before the opposing party serves an answer or a motion for summary judgment.
Because no court ruled on validity, infringement, or claim construction, this case generates no binding precedent on the underlying patent’s enforceability. For pharmaceutical patent practitioners, this reinforces that early-stage voluntary dismissal is not a concession of weakness but often a deliberate strategic repositioning.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View related patents in this pharmaceutical space
- See which companies are most active in injectable drug patents
- Understand claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Pharmaceutical Injectables & Formulations
1 Patent Involved
US11786548B2 specifically
Rule 41 Dismissal
Plaintiff retains right to re-file
✅ Key Takeaways
Rule 41(a)(1)(A)(i) dismissals without prejudice preserve re-filing rights and are powerful tactical instruments in early-stage pharmaceutical patent disputes.
Search related case law →Multi-defendant complaints targeting supply chains are an increasingly common enforcement architecture in specialty pharmaceutical litigation.
Explore litigation strategies →Frequently Asked Questions
U.S. Patent No. US11786548B2 (application US17/365695), covering Trace Elements Injection 4*, USP formulations in single-dose and pharmacy bulk package vials.
American Regent filed a voluntary dismissal without prejudice under Fed. R. Civ. P. 41(a)(1)(A)(i) after 41 days, before defendants formally appeared. The precise reason — whether settlement, licensing, or strategic reassessment — was not publicly disclosed.
Yes. A dismissal without prejudice explicitly preserves the plaintiff’s right to re-file the same claims subject to applicable limitations periods.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case 1:24-cv-00268
- USPTO Patent Center — US11786548B2
- Cornell Legal Information Institute — Fed. R. Civ. P. 41(a)(1)(A)(i)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.